87178-63-0
Chemical Structure
Leucylproline hydrochloride
Synonym(s): Leu-Pro hydrochloride
- CAS No.: 87178-63-0
- Formula:C11H21ClN2O3
- Molecular Weight:264.75
IUPAC Name: L-leucyl-L-proline hydrochloride
InChIKey: GZEPUBCBTCSTKP-OZZZDHQUSA-N
SMILES: O=C([C@H]1N(CCC1)C([C@@H](N)CC(C)C)=O)O.Cl
Biological Activity:
Leucylproline hydrochloride (Leu‑Pro hydrochloride) is a dipeptide composed of L‑leucine and L‑proline, and it is a fecal secondary metabolite associated with the gut microbiota. Leucylproline hydrochloride is taken up by Lactococcus lactis cells via the di‑tripeptide transport system, and mediates transcriptional repression of the prtP/prtM promoter after intracellular accumulation. The content of Leucylproline hydrochloride is significantly decreased in fecal samples related to hepatolenticular degeneration. Leucylproline hydrochloride can be used for the study of metabolism‑related diseases[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Leucylproline hydrochloride | 99.61% | Leucylproline hydrochloride (Leu‑Pro hydrochloride) is a dipeptide composed of L‑leucine and L‑proline, and it is a fecal secondary metabolite associated with the gut microbiota. Leucylproline hydrochloride is taken up by Lactococcus lactis cells via the di‑tripeptide transport system, and mediates transcriptional repression of the prtP/prtM promoter after intracellular accumulation. The content of Leucylproline hydrochloride is significantly decreased in fecal samples related to hepatolenticular degeneration. Leucylproline hydrochloride can be used for the study of metabolism‑related diseases. |
||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Marugg JD, et al. Medium-dependent regulation of proteinase gene expression in Lactococcus lactis: control of transcription initiation by specific dipeptides. Journal of bacteriology. 1995 Jun;177(11):2982-9.
- [2]. Cai X, et al. Multi-omics study unravels gut microbiota and metabolites alteration in patients with Wilson's disease. Scientific reports. 2024 Sep 09;14(1):21025.
